Program
JNJ-98768111
A development code.
Its studies are mostly in Prostatic Neoplasms, led by Johnson & Johnson.
Furthest: phase 1, since Jul 31, 20261 company-led study, 1 open or runningNext primary completion: Mar 16, 2029 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 11 open or running | phase 1since Jul 31, 2026 | Jul 31, 2026 | Mar 16, 2029phase 1 · NCT07746713 |
- Named in Johnson & Johnson’s own pipeline as
JNJ-8111
, phase 1, as of Oct 13, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 31, 2026First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT07746713 · 160 planned · United States, Israel
Ahead
- Mar 16, 2029Primary completion: phase 1 study in Prostatic NeoplasmsNCT07746713
TargetBeta
“A Phase 1 Trial of JNJ-98768111, an Antibody Drug Conjugate (ADC) Targeting Human Kallikrein-2 (KLK2) for Advanced Prostate Cancer”study text, read by Claude · the study
Other programs on KLK2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| pasritamig | Johnson & Johnson | phase 3 | 5 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07746713Prostatic Neoplasms · United States, Israel | 1 | Recruiting | Mar 16, 2029 | 160 |
How it is read
Names in the registry
- “JNJ-98768111”, 1 entry
Codes read as this program: JNJ98768111.
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.